Yagi Shusuke, Aihara Ken-Ichi, Ikeda Yasumasa, Akaike Masashi, Sata Masataka, Matsumoto Toshio
Department of Cardiovascular Medicine, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
Int J Vasc Med. 2012;2012:162545. doi: 10.1155/2012/162545. Epub 2012 Jun 26.
Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.
心血管疾病与肾脏疾病关系密切,形成了一种恶性循环,即心肾综合征(CRS)。当传统心血管危险因素积累激活肾素-血管紧张素-醛固酮系统时,氧化应激、内皮功能障碍和血管炎症可能成为治疗靶点;然而,CRS的管理策略尚未确立。他汀类药物,即HMG-CoA还原酶抑制剂,不仅具有降低胆固醇的作用,还对心血管系统具有多效性作用,包括抗炎、抗氧化作用以及改善一氧化氮生物利用度。由于最近的研究表明,他汀类药物以依赖或不依赖降低胆固醇的方式对慢性肾脏病、心力衰竭以及冠状动脉疾病均有有益作用,因此使用他汀类药物治疗可能是预防CRS恶化的成功策略。